Acurx PharmaceuticalsACXP
Market Cap: 36.1M
About: Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Employees: 4
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
13% more funds holding
Funds holding: 23 [Q4 2023] → 26 (+3) [Q1 2024]
13% more call options, than puts
Call options by funds: $117K | Put options by funds: $104K
0.7% more ownership
Funds ownership: 7.93% [Q4 2023] → 8.63% (+0.7%) [Q1 2024]
27% less capital invested
Capital invested by funds: $4.18M [Q4 2023] → $3.05M (-$1.13M) [Q1 2024]
Research analyst outlook
3 Wall Street Analysts provided 1 year price forecasts over the past 6 months
3 analyst ratings
HC Wainwright & Co. Ed Arce | 426%upside $12 | Buy Reiterated | 16 May 2024 |
HC Wainwright & Co. Ed Arce | 426%upside $12 | Buy Maintained | 19 Mar 2024 |
HC Wainwright & Co. Ed Arce | 514%upside $14 | Buy Reiterated | 28 Feb 2024 |
Financial journalist opinion
Based on 3 articles about ACXP published over the past 30 days